TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01466959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: citrate dialysate (CD)
Description: Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acetic-acid based dialysate (AD)
Description: Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
Study: NCT02102022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 plus modified FOLFOX6
Study: NCT01772394

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Description: The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
Study: NCT01749618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Feedback
Description: Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
Study: NCT04537130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IN01 vaccine
Description: INO1 vaccine is a biological compound comprising generated and purified from recombinant bacteria culture that contains a protein consisting of EGF-4-EGF portion and the Cholera Toxin B-Subunit Domain G33D sequence (CTB-G33D) separated by 4 amino acids and 14 amino acids respectively glycine/serine-rich linkers.~IN01 is a recombinant growth factor fusion molecule which, once injected into the patient, stimulates the immune system to produce polyclonal anti-Epidermal Growth Factor (anti-EGF) neutralizing antibodies. This vaccine-led active immunisation is a new approach to target the growth factor pathways allowing for combinations with other small molecule inhibitors in order to obtain a sustained efficacy with an acceptable toxicity.~The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor growth or other pathophysiologies such as fibrosis.
Study: NCT01063439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Etoposide, Cytarabine, Melphalan
Description: Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
Study: NCT06250621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: Implants were placed by means of a template for a guided surgery approach (GD Group) or with a standard free-hand surgical approach without any additional device (FH Group). A non expert doctor (less that 20 implants placed in the professional activity) was selected for the procedures related to the GD Group; a skilled operator (more than 1000 implants placed in the professional activity) was selected for the procedures related to the FH Group, respectively.~A two-stage surgical technique was chosen. Implants were placed (Anyridge, Megagen Implants, Seoul, Korea) 1 mm below the crestal level, as recommended by the manufacturer. After flap elevation the height of the supra-crestal soft tissue (STH) was measured by means of a calibrated probe.~An inter-implant distance of 3 mm at least, and/or an interproximal space from 1.5 to 3 mm between an implant and the adjacent tooth were observed.~Flaps were sutured over the implants to allow a submerged healing.
Study: NCT04468295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital models
Description: impression taking and digital scanning
Study: NCT02764671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10μg/0.5ml recombinant hepatitis B vaccine
Description: 5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
Study: NCT02568189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoSite Maxx Series Ultrasound System
Description: Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SonoSite Maxx Series Ultrasound System
Description: Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoSite Maxx Series Ultrasound System
Description: Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SonoSite Maxx Series Ultrasound System
Description: Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.
Study: NCT03166709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventing Addiction Related Suicide (PARS)
Description: PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; The Strong Link Between Addiction and Suicide; Suicide Myths and Facts; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs of Suicide; Suicide Risk Factors; Suicide Protective Factors; How You Can Prevent Addiction Related Suicide; Action Steps to Take if You or Someone You Know Becomes Suicidal

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Outpatient Program standard session
Description: Intensive Outpatient Program (IOP) substance abuse group session focused on depression, grief, or managing emotions. Site-specific session topic is what that IOP usually provides and was chosen by agency leads prior to start of study.
Study: NCT03173521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2/8.TBG.hARSB
Description: Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Four dose levels are available:~* Starting dose is 6x1011 gc of vector per kg of body weight;~* High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT;~* Very high dose is 6x1012 vector per kg of body weight and will be administered after three subjects at the high dose have experienced no DLT;~* Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg.
Study: NCT01104935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab monotherapy
Study: NCT01571323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin and Misoprostol
Description: The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
Study: NCT04223336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief physical activity and diet intervention
Description: The intervention is an integrated care pathway that provides a computerized prompts for practitioners in the STOP program via their online portal. For a participant who is in the intervention group, the online portal will screen the participant for their physical activity and fruit/vegetable consumption and provide the practitioner (who is seeing this participant for their visit) with computerized alerts for physical activity and fruits/vegetable consumption. Specifically, the portal will prompt practitioners to provide a brief intervention for these two behaviours using risk communication and will also suggest brief intervention language designed based on the Elicit-Provide-Elicit framework. The portal will also have available a self-monitoring resource for physical activity and fruits/vegetable consumption and will prompt practitioners to provide this self-monitoring resource to the participant during their visit.
Study: NCT01104935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab and chemotherapy
Study: NCT04468295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: measurement
Description: Assessment the rate of retraction for 6 months
Study: NCT02742818

Intervention type: DEVICE
Group type: OTHER
Intervention: Upper body blanket, Bair Hugger
Description: Upper body warming blanket will be used in patients undergoing LEA and EVAR.

Intervention type: DEVICE
Group type: OTHER
Intervention: Underbody blanket, Bair Hugger
Description: Underbody warming blanket will be used in patients undergoing LEA and EVAR.
Study: NCT03740828

Intervention type: DEVICE
Intervention: KIDScore D3
Description: Embryos are scored using the KIDScore D3 algorithm based on annotated morphokinetic parameters.
Study: NCT00913861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypnosis
Description: Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
Study: NCT02446067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
Study: NCT03393923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of the anterior wedge
Description: Application of anterior wedge in tennis
Study: NCT00913861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard sedation
Description: Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
Study: NCT03440229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emulsifier-containing diet
Description: CMC is one of many synthetic dietary emulsifiers that are incorporated into a variety of processed foods. We have recently shown that, in mice, consumption of P80 and CMC, alters microbiota composition, have pro-inflammatory potential and promote microbiota encroachment into the colonic mucosa, low-grade inflammation, and metabolic syndrome. However, it is not known whether these compounds have similar effects in humans. We would like to study these effects in the human gut microbiota.
Study: NCT04468295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: measurement
Description: Assessment the rate of retraction for 6 months
Study: NCT00793962

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionation radiotherapy
Description: radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional fractionation radiotherapy
Description: 50Gy/25/f/5w
Study: NCT03769441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Four intravenous dosages of ferric(III) carboxymaltose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Four intravenous dosages of sodiumchloride
Study: NCT03175536

Intervention type: OTHER
Intervention: HDHP with PDL
Description: Enrollment in a Health Savings Account-eligible high-deductible health plan with an annual individual deductible of \>$1000 that includes a preventive drug list (a list of certain chronic medications that are exempt from the deductible)
Study: NCT04115319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP363856
Description: SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine XR
Description: quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
Study: NCT00677521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: 50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
Study: NCT00913861

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured attention
Description: Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
Study: NCT01622257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavitation US
Description: The areas with localized fat are treated 2 times per week for 3 months using Aesthetic cavitation via ultrasonic cavitation machine (Cavi SMART, South Korea, supplied with one piece cavitation probe of 40 KHz, 3-6 watt(W)/cm\^2 adjustable, 60W with 20cm\^2 active surface).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin hydrochloride (Glucophage 500 mg/tablet, Bristol-Myers Squibb, New York, USA). Medication is initiated in a step-up fashion every 5 days, from one tablet per day to three. This dose is maintained as tolerated throughout the 3 months of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cavitation US + Metformin
Description: Combination of both Cavitation US + Metformin. the treatment duration lasts 3 months
Study: NCT00497068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tobacco abstinent contingent
Description: Participants receive vouchers wiht monetary rewards for providing breath samples that show tobacco smoking abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: non-contingent
Description: Participants receive vouchers regardless of tobacco use status

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control
Description: this group receives no vouchers
Study: NCT03446716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Child attempted to go to bed 90 mins in advance of their normal bedtime.
Study: NCT01325896

Intervention type: DRUG
Group type: OTHER
Intervention: PEG-Intron sc injection
Description: This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.~PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.~Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse.
Study: NCT01393548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brompheniramine + phenylephrine
Description: Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.~OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient.
Study: NCT04802486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXCAP©®
Description: EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
Study: NCT01352195

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forever Free Booklets
Description: Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forever Free Booklets
Description: Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forever Free Booklets
Description: Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.
Study: NCT03808649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1500ml of 2.5% mannitol
Description: 1500ml of 2.5% mannitol was used in experimental group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1500ml of 2.5% mannitol
Description: 1500ml of 2.5% mannitol was used in experimental group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: different volume of 2.5% mannitol
Description: different volume of 2.5% mannitol based on BMI was used in active comparator group
Study: NCT03059017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol Sulphate
Description: salbutamol sulphate packaged as aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niosomes
Description: Niosomes
Study: NCT00861640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Omeprazole
Description: Intravenous Omeprazole 1amp qd (every day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Rabeprazole
Description: Oral Rabeprazole 1 bid
Study: NCT01393548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brompheniramine + pseudoephedrine
Description: Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
Study: NCT03053752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
Study: NCT00365794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical testosterone gel 10 g/day
Description: Testosterone gel therapy for 20 weeks
Study: NCT03618693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Injection of a single shot of local anesthetic bupivacaine 0.5% combined with 20 mcg fentanyl intrathecally.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: TAP block with a single shot of 20ml ropivacaine 0.375% combined with 75 mcg clonidine bilaterally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Concomitant systemic administration of lidocaine (as an adjuvant) to the standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.